COX‐1 inhibition depletes protective PGE2,25, 26 resulting in increased production of cysteinyl‐leukotrienes27 that leads to symptoms ranging from urticaria to anaphylaxis.25 The gene discussed is MT-CO1; the disease is anaphylaxis.